Vaxcyte

📍 San Carlos, United States🗓 Founded 2013👥 592 employees💰 Last funded Jul 2026
Biotechnology Research🌐 vaxcyte.com
Website LinkedIn
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.
9
Total investors
0
Early stage
0
Mid stage
0
Late stage
2013
Founded

Investors

9 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
9
Investor activity2015–2026 · investors recorded per year
2015220172201822020220261
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Vaxcyte?
Vaxcyte has 9 investors on record on gritt.io.
When did Vaxcyte last raise funding?
The most recent investment in Vaxcyte recorded on gritt.io was in July 2026.
When was Vaxcyte founded?
Vaxcyte was founded in 2013.
What industry is Vaxcyte in?
Vaxcyte operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Vaxcyte based?
Vaxcyte is headquartered in San Carlos, United States.